Avanir Pharmaceuticals Inc., of Aliso Viejo, Calif., said it reached a resolution of civil, criminal and administrative claims with the federal government and participating state authorities. In February, the company reported that an agreement in principle had been reached regarding certain sales and marketing practices for its product, Nuedexta (dextromethorphan hydrobromide and quinidine sulfate) 20 mg/10 mg capsules, a treatment for pseudobulbar affect, prior to 2017. Under the agreements, the company will pay approximately $116 million to federal and state governments. As a part of the resolution, Avanir has entered into a False Claims Act agreement with various government agencies, a Deferred Prosecution agreement with the U.S. Department of Justice for a period of three years, and a Corporate Integrity agreement with the U.S. Department of Health and Human Services Office of Inspector General for a period of five years.

No Comments